The University of Science and Technology of China (USTC) research internship program provides the opportunity for graduate students or 3rd/4th year undergraduate students to participate in research projects to gain valuable experience on a variety of cutting-edge research at USTC.

Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for AXS-05 seeking approval for the treatment of agitation associated with Alzheimer’s disease, and has granted Priority Review designation to the filing. The regulatory body has set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026, underlining the importance of this potential new therapy in an area of high unmet need.

A new peer-reviewed study has revealed that Sanghuangporus quercicola, a medicinal fungus long used in traditional practices across Asia, produces significantly varied secondary metabolites under different cultivation conditions, with notable in vitro antidiabetic activity emerging from the analyses.